Correction: Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban and Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation
- PMID: 36375167
- DOI: 10.7326/L22-0406
Correction: Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban and Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation
Erratum for
-
Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.Ann Intern Med. 2021 Jul;174(7):910-919. doi: 10.7326/M20-6194. Epub 2021 Mar 30. Ann Intern Med. 2021. PMID: 33780291
-
Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.Ann Intern Med. 2022 Jan;175(1):20-28. doi: 10.7326/M21-0717. Epub 2021 Dec 7. Ann Intern Med. 2022. PMID: 34871048
Publication types
LinkOut - more resources
Full Text Sources